当前位置: 首页 > 期刊 > 《医药产业资讯》 > 2016年第18期 > 正文
编号:12868337
抗血管生成治疗耐药与肿瘤微环境关系的研究进展(5)
http://www.100md.com 2016年6月25日 《中国医药导报》2016年第18期
     [25] Poschke I,Kiessling R. On the armament and appearances of human myeloid-derived suppressor cells [J]. Clin Immunol,2012,144(3):250-268.

    [26] Shojaei F,Wu X,Malik AK,et al. Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+myeloid cells [J]. Nat. Biotechnol,2007,25(8):911-920.

    [27] Huang Y,Carbone DP. Mechanisms of and strategies for overcoming resistance to anti-vascular endothelial growth factor therapy in non-small cell lung cancer [J]. Biochim Biophys Acta,2015,1855(2):193-201.

    [28] Hillen F,Griffioen AW. Tumour vascularization:sprouting angiogenesis and beyond [J]. Cancer Metastasis Rev,2007,26(3-4):489-502.

    [29] Zhou TJ,Huang XH,Gong L,et al. Vasculogenic mimicry and hypoxia-inducible factor-1α expression in cervical squamous cell carcinoma [J]. Genetics and Molecular Research,2016,15(1). doi: 10.4238.

    [30] Huang B,Xiao E,Huang M. MEK/ERK pathway is positively involved in hypoxia-induced vasculogenic mimicry formation in hepatocellular carcinoma which is regulated negatively by protein kinase A [J]. Med Oncol,2015,31(1):408-419.

    (收稿日期:2016-02-28 本文编辑:赵鲁枫) (钱祥云 戈伟)
上一页1 2 3 4 5